Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nonmyeloablative Allo-SCT for Relapsed Lymphoma
NCT00121186Phase 2Terminated
- Sponsor
- SWOG Cancer Research Network
- Start
- Jul 2005
- Primary completion
- Jan 2008
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fludarabine and melphalan in Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), sponsored by SWOG Cancer Research Network. Primary endpoints: Progression-free Survival at 1 year and Overall Survival at 1 year. Started Jul 2005; status: terminated.
02
Drugs
fludarabinemelphalan
03
Conditions
Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00121186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00121186.